Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.22 USD
−259.34 M USD
0.00 USD
62.27 M
About Immunovant, Inc.
Sector
Industry
CEO
Peter Salzmann
Website
Headquarters
New York
Founded
2018
FIGI
BBG00P5MC0Q8
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IMVT is 24.37 USD — it has decreased by −0.18% in the past 24 hours. Watch Immunovant, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Immunovant, Inc. stocks are traded under the ticker IMVT.
IMVT stock has fallen by −5.51% compared to the previous week, the month change is a −15.15% fall, over the last year Immunovant, Inc. has showed a −42.35% decrease.
We've gathered analysts' opinions on Immunovant, Inc. future price: according to them, IMVT price has a max estimate of 58.00 USD and a min estimate of 44.00 USD. Watch IMVT chart and read a more detailed Immunovant, Inc. stock forecast: see what analysts think of Immunovant, Inc. and suggest that you do with its stocks.
IMVT reached its all-time high on Nov 18, 2020 with the price of 53.75 USD, and its all-time low was 3.15 USD and was reached on Jun 13, 2022. View more price dynamics on IMVT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
IMVT stock is 2.04% volatile and has beta coefficient of 0.44. Track Immunovant, Inc. stock price on the chart and check out the list of the most volatile stocks — is Immunovant, Inc. there?
Today Immunovant, Inc. has the market capitalization of 3.59 B, it has decreased by −0.65% over the last week.
Yes, you can track Immunovant, Inc. financials in yearly and quarterly reports right on TradingView.
Immunovant, Inc. is going to release the next earnings report on Feb 12, 2025. Keep track of upcoming events with our Earnings Calendar.
IMVT earnings for the last quarter are −0.74 USD per share, whereas the estimation was −0.59 USD resulting in a −25.69% surprise. The estimated earnings for the next quarter are −0.74 USD per share. See more details about Immunovant, Inc. earnings.
Immunovant, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
IMVT net income for the last quarter is −109.12 M USD, while the quarter before that showed −87.15 M USD of net income which accounts for −25.21% change. Track more Immunovant, Inc. financial stats to get the full picture.
No, IMVT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 207.00 employees. See our rating of the largest employees — is Immunovant, Inc. on this list?
Like other stocks, IMVT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Immunovant, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Immunovant, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Immunovant, Inc. stock shows the sell signal. See more of Immunovant, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.